Facile fabrication of an extended‐release tablet of Ticagrelor using three dimensional printing technology

Abstract

AbstractThe objective of the study was to fabricate tailored extended‐release tablets of blood thinner Ticagrelor as once‐daily dosing using additive manufacturing for better compliance in heart failure therapy. The solid work design of the tablet was printed using hot melt extrusion (HME) based 3D printing by optimized mixture of Eudragit RS‐100, plasticizer and drug for producing extrudable and printable filaments. FTIR and TGA results showed no covalent interaction among ingredients and no decomposition during HME process, respectively. Friability, weight variation, assay and content uniformity tests met USP requirements, while the mean hardness of the tablets was calculated in a value between 40 and 50 kg. According to DSC and XRD results, the crystallinity state of the Ticagrelor was converted to an amorphous one in the tablet matrix. Smooth surfaces with multiple deposited layers were observed using SEM. In comparison, the maximum Ticagrelor release of 100% after 120 min from Brilinta® tablets was decreased to 97% in 400 min from the 3D tablet at infill of 90%. Korsmeyer‐Peppas kinetic model showed the drug release mechanism is affected by diffusion and swelling. In general, fabrication of the extended‐release 3D printed tablet of Ticagrelor using HME‐based‐additive manufacturing has the potential to provide specific doses with tailored kinetic release for personalized medicine, improving adherence at point‐of‐care.